查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947952

PrEP藥物市場依產品類型、給藥途徑、通路及作用機制分類，全球預測，2026-2032年

Drugs for PrEP Market by Product Type, Administration Route, Distribution Channel, Mechanism Of Action - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，預防性暴露前 (PrEP) 藥物市值將達到 23.4 億美元，到 2026 年將成長至 25.1 億美元，複合年成長率為 8.26%，到 ​​2032 年將達到 40.8 億美元。

關鍵市場統計數據
基準年 2025 23.4億美元
預計年份：2026年 25.1億美元
預測年份 2032 40.8億美元
複合年成長率 (%) 8.26%

本文將介紹一個充滿活力的PrEP預防環境，該環境旨在將臨床創新與獲取和交付的實際情況相結合。

由於治療方法創新、醫療服務模式轉變以及支付方和政策環境的變化，愛滋病毒暴露前預防（PrEP）領域正經歷快速變革。近期臨床進展擴大了高風險族群可選擇的方案，同時醫療系統和社區服務提供者也在調整服務路徑，以提高藥物利用率和病患依從性。在此背景下，相關人員必須權衡長效製劑的優勢與常規口服療法的既有作用，以確保臨床獲益能夠轉化為實際可及性和公平的結果。

臨床創新、不斷發展的醫療服務模式以及支付方政策如何融合，共同推動PrEP生態系統的變革

過去幾年發生的變革性變化正在重塑暴露前預防（PrEP）的研發、實施和資金籌措方式。最顯著的是，長效注射劑的出現挑戰了傳統口服藥物的優勢，因為它能提高用藥依從性，並帶來新的服務提供機會。隨著越來越多的證據表明注射劑在不同人群中的有效性，臨床醫生和醫療系統正在重新思考支持定期就診、注射給藥和監測的護理模式，這反過來又影響著服務提供地點的經濟效益和人力資源規劃。同時，監管部門的核准和指南的更新正在擴大適應症範圍，並為風險分層提供新的見解，迫使支付方重新評估藥物清單和事先核准框架。

評估2025年美國關稅調整對PrEP供應鏈和支付方趨勢的累積營運和取得影響

2025年實施的累積關稅調整引入了新的經濟變量，影響PrEP產品的供應鏈設計、採購選擇和定價策略。進口原料藥、製劑和包裝組件的關稅提高，將增加品牌藥和非專利生產商的到岸成本，尤其是那些依賴跨境原料採購的供應鏈。為此，生產商和契約製造生產商正在評估近岸外包、垂直整合和替代籌資策略，以保護利潤率並維持供應可靠性。同時，採購部門正在重新考慮供應商多元化，以降低集中風險。

深入的細分洞察，詳細闡述產品類型、給藥途徑、最終用戶、分銷管道和作用機制如何共同影響策略選擇。

對PrEP市場進行細分，可以揭示臨床、商業性和營運方面的差異，這些差異應指南策略規劃。從產品類型來看，市場由品牌產品（例如長效卡博特韋和已上市的口服組合藥物）和學名藥（主要是TDF/FTC）組成，兩者在臨床特徵、專利過渡和定價動態方面均存在差異。這些差異會影響生產規模、產品系列部署順序和患者覆蓋範圍等方面的決策，因為品牌長效藥物可以建立高階定位，而學名藥有可能擴大患者的可及性。

從區域觀點分析獲取和使用情況，揭示了系統和資金籌措不同的暴露前預防（PrEP）推廣策略。

區域趨勢顯著影響暴露前預防（PrEP）介入措施的推廣途徑和實施重點。儘管美洲擁有成熟的法規環境和完善的預防項目，但取得途徑仍有差異。支付方合作和全面護理模式推動了都市區的推廣，而地方社區計畫對於涵蓋邊緣化人群至關重要。政策變化、採購框架和本地生產能力進一步加劇了該地區各國應對措施的差異。

關鍵的競爭考察和夥伴關係洞察凸顯了品牌差異化、學名藥和分銷合作關係將如何影響現實世界中PrEP的覆蓋範圍和普及程度。

PrEP領域的競爭格局呈現出現有品牌所有者、創新產品參與企業和不斷壯大的非專利藥生產商之間的平衡。銷售長效製劑的品牌所有者已在臨床開發和醫護人員培訓方面投入巨資，以支持診所內的給藥；而銷售口服複方製劑的公司則強調便利性、患者援助計劃和廣泛的藥房分銷。學名藥藥生產商在提高藥物的可負擔性和可及性方面發揮著至關重要的作用，尤其是在那些採購機制優先考慮成本控制和批量採購的地區。

為產業領導者提供切實可行的建議，以確保供應韌性、最佳化交付並加速公平取得PrEP創新產品。

為了鞏固預防成果，產業和政策領導者必須將洞見轉化為具體行動。首先，投資多元化供應鏈和關鍵材料的雙重採購將有助於降低貿易政策波動帶來的風險，並確保供應的連續性。其次，產品開發必須與實際供應情況相符。製造商在設計臨床方案和包裝時，應考慮在醫療機構和社區環境中的便利性，並開發能夠滿足不同終端使用者需求的依從性支援措施。

一種透明、以證據為基礎的調查方法，整合了相關人員的見解、監管審查和營運分析，以支持策略決策。

支撐這些發現的研究採用了多方面的方法，其核心是與關鍵相關人員的互動、臨床證據綜合以及營運分析。研究人員對臨床醫生、藥劑師、支付方代表、採購負責人和患者權益倡導團體進行了結構化訪談，以了解他們對處方行為、依從性障礙和通路動態的實地觀點。為了確保技術準確性和與當前實踐的相關性，研究人員將這些定性研究結果與監管核准、指南修訂和已發表的臨床試驗結果的系統性回顧進行了三角驗證。

綜合臨床進展、服務需求和政策考量，為實際的暴露前預防（PrEP）決策提供指導。

總之，在治療方法創新、不斷演進的照護模式和不斷變化的政策槓桿的推動下，PrEP領域正處於策略轉折點。長效注射劑在提高依從性和維持率方面展現出令人矚目的優勢，但要充分發揮其潛力，需要重組給藥途徑並加強支付方的參與。同時，口服每日製劑對於廣泛且分散的用藥途徑仍然至關重要，尤其是在藥房和線上管道能夠促進治療啟動和維持的地區。產品類型、給藥途徑、最終用戶需求、通路和作用機制之間的相互作用，為生產者、支付方和醫療服務提供者建立了一個複雜但又可控的決策矩陣。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的PrEP藥物市場

  • 品牌產品
    • 練習曲
    • 德斯科維
    • Truvada
  • 學名藥

9. 按給藥途徑分類的PrEP藥物市場

  • 注射
  • 口服

第10章 按分銷管道分類的PrEP藥物市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

11. 按作用機轉分類的PrEP藥物市場

  • 整合酶鏈轉移抑制劑
  • 核苷酸逆轉錄酶抑制劑

第12章 各地區PrEP藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按組別分類的PrEP藥物市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國PrEP藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國PrEP藥物市場

第16章：中國PrEP藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Emcure Pharmaceuticals Limited
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Janssen Pharmaceuticals, Inc.
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Merck KGaA
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4F7A6D4FB6A2

The Drugs for PrEP Market was valued at USD 2.34 billion in 2025 and is projected to grow to USD 2.51 billion in 2026, with a CAGR of 8.26%, reaching USD 4.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.34 billion
Estimated Year [2026] USD 2.51 billion
Forecast Year [2032] USD 4.08 billion
CAGR (%) 8.26%

An orienting introduction to the dynamic PrEP prevention landscape, aligning clinical innovation with access and delivery realities

The prevention landscape for HIV pre-exposure prophylaxis (PrEP) is undergoing rapid transformation driven by therapeutic innovation, shifting care delivery models, and evolving payer and policy environments. Recent clinical advances have broadened the options available to individuals at risk, while health systems and community providers are adapting care pathways to improve uptake and persistence. Against this backdrop, stakeholders must reconcile the promise of long-acting modalities with the entrenched role of daily oral therapies, ensuring that clinical benefits translate into real-world access and equitable outcomes.

This introduction situates readers in the current environment, emphasizing the dual imperative of clinical efficacy and programmatic feasibility. It highlights how product characteristics, administration routes, and end-user needs intersect to shape decisions across manufacturers, payers, and providers. By framing the discussion around access, adherence, and delivery, the following sections explore the forces redefining PrEP strategy and offer a structured lens for evaluating investment, commercialization, and policy options. As the landscape evolves, organizations that align scientific innovation with pragmatic distribution and reimbursement tactics will be best positioned to expand prevention impact.

How clinical innovation, care delivery evolution, and payer policy are converging to drive transformative shifts across the PrEP ecosystem

The past several years have produced transformative shifts that are reshaping how PrEP is developed, delivered, and financed. A notable pivot toward long-acting injectable formulations has challenged the dominance of daily oral therapy by offering adherence advantages and novel service delivery opportunities. As evidence mounts for injectable agents in diverse populations, clinicians and health systems are reconsidering care models to support periodic clinic visits, injection administration, and monitoring, which in turn influences site-of-care economics and workforce planning. Concurrently, regulatory approvals and guideline updates have broadened indications and informed risk stratification, prompting payers to revisit formulary placement and prior authorization frameworks.

Beyond therapeutics, digital health and telemedicine have accelerated patient identification, initiation, and follow-up, bridging gaps created by geographic and social barriers. Community-based distribution and pharmacy engagement have expanded, enabling decentralized access while creating new partnerships between manufacturers and nontraditional channels. These converging trends underscore a shift from product-centric strategies to ecosystem-centric approaches, where success depends on coordinated clinical evidence generation, stakeholder alignment, and flexible distribution models that meet the needs of heterogeneous end users.

Assessing the cumulative operational and access implications of United States tariff shifts enacted in 2025 on PrEP supply chains and payer dynamics

The introduction of cumulative tariff changes in 2025 has introduced a new economic variable that affects supply chain design, procurement choices, and pricing strategies for PrEP products. Higher duties on imported active pharmaceutical ingredients, finished dosage forms, and packaging components increase landed input costs for both branded and generic producers, particularly when supply chains rely on cross-border sourcing of bulk materials. In response, manufacturers and contract manufacturers are evaluating nearshoring, vertical integration, and alternative sourcing strategies to protect margins and maintain supply reliability, while procurement teams reassess supplier diversification to mitigate concentration risk.

These trade measures also influence payer negotiations and formulary decision making. Where incremental cost pressures emerge, payers may tighten utilization management or accelerate value-based contracting conversations that tie reimbursement to adherence or clinical outcomes. Health systems that self-procure for hospital pharmacies and clinics face budgetary strain that can alter stocking practices and ordering cadence. At the same time, tariffs create an impetus for investment in domestic manufacturing capacity and bilateral trade agreements that could, over time, reduce exposure to external shocks. Overall, the policy environment introduced by 2025 tariffs highlights the need for strategic supply chain planning, transparent cost modeling, and collaborative approaches among manufacturers, payers, and health systems to preserve access to PrEP therapies.

Deep segmentation insight detailing how product type, administration route, end user, distribution channel, and mechanism of action jointly shape strategic choices

Segmenting the PrEP landscape reveals differentiated clinical, commercial, and operational implications that must guide strategy. Looking at product type, the landscape spans branded options-such as long-acting cabotegravir and established oral combinations-and generic formulations centered on TDF/FTC, each with distinct clinical profiles, patent trajectories, and pricing dynamics. These differences affect decisions about manufacturing scale, portfolio sequencing, and patient outreach, as branded long-acting agents may command premium positioning while generics drive broader accessibility.

When considering administration route, injectable therapies change the locus of care by requiring clinic-based encounters for long-acting dosing schedules, whereas daily oral regimens enable decentralized initiation and continuity through community and pharmacy channels. End user segmentation further refines targeting: prevention programs for men who have sex with men must integrate culturally competent outreach and rapid initiation pathways, while strategies for heterosexual adults and people who inject drugs require tailored adherence support, harm reduction alignment, and linkage to social services.

Distribution channel segmentation clarifies operational choices: hospital pharmacies play a critical role for clinic-administered injectables, online pharmacies expand reach for oral regimens, and retail pharmacies-both chain and independent-serve as essential access points for routine dispensing and patient counseling. Finally, mechanism of action distinctions-between integrase strand transfer inhibitors implemented as cabotegravir and nucleotide reverse transcriptase inhibitor options differentiated by TAF-based and TDF-based chemistries-inform clinical positioning, monitoring needs, and resistance stewardship. Together, these intersecting segmentations should drive differentiated commercialization, access planning, and evidence generation.

Regional lenses on access and adoption revealing how geographic variability in systems and financing drives differentiated PrEP deployment strategies

Regional dynamics significantly influence adoption pathways and operational priorities for PrEP interventions. In the Americas, a mature regulatory environment and established prevention programs coexist with persistent disparities in access; payer engagement and integrated care models drive uptake in urban centers, while community programs remain essential for reaching marginalized populations. Policy changes, procurement frameworks, and local manufacturing capacities further differentiate national responses across the region.

In Europe, Middle East & Africa, diversity in health system maturity and financing mechanisms produces heterogenous adoption patterns. High-income countries in Europe typically align guideline updates with systematic reimbursement pathways, enabling rapid incorporation of new modalities, whereas many countries in Africa and parts of the Middle East rely on donor programs, national guidelines, and task-shifting to scale preventive services. Supply chain resilience and affordability are central concerns, and partnerships with global procurement agencies often shape availability.

Across Asia-Pacific, a mix of large public programs, evolving private sector engagement, and variable regulatory timelines creates a nuanced landscape. Several countries are investing in domestic manufacturing and regulatory harmonization, which can shorten pathways for local supply, while others leverage private pharmacies and telehealth to expand access. Each region's structural characteristics-funding models, care delivery norms, and manufacturing footprints-should inform tailored strategies for product launch, distribution, and stakeholder engagement.

Key competitive and partnership insights highlighting how brand differentiation, generics, and distribution alliances determine real-world PrEP reach and uptake

Competitive dynamics in the PrEP arena reflect a balance between established brand owners, innovative modality entrants, and an expanding base of generic manufacturers. Brand owners that commercialize long-acting formulations have invested heavily in clinical development and provider education to support clinic-based administration, while companies with oral combination products have emphasized convenience, patient support programs, and broad pharmacy distribution. Generic manufacturers play a pivotal role in expanding affordability and access, especially in regions where procurement mechanisms prioritize cost containment and volume purchasing.

Partnerships between producers and distributors, plus collaborations with public health agencies and community organizations, increasingly determine real-world reach. Manufacturers that integrate demand generation with robust supply commitments, patient assistance frameworks, and clinician training gain traction across care settings. Additionally, innovators are exploring value partnerships with payers to align pricing with outcomes and adherence measures. Overall, competitive advantage accrues to organizations that combine clinical differentiation with pragmatic delivery models, resilient supply chains, and targeted stakeholder engagement across public and private channels.

Actionable recommendations for industry leaders to secure supply resilience, optimize delivery, and accelerate equitable access to PrEP innovations

Leaders across industry and policy spheres must translate insights into concrete actions to ensure sustained prevention impact. First, investing in diversified supply chains and dual sourcing for critical inputs will reduce exposure to trade policy shocks and preserve continuity of supply. Second, aligning product development with real-world delivery realities is essential; manufacturers should design clinical programs and packaging for ease of administration in both clinic and community settings, and develop adherence supports that reflect the needs of distinct end users.

Third, proactive payer engagement is critical to secure predictable access pathways. Early dialogue that links clinical value to outcomes and operational feasibility can streamline reimbursement and reduce initiation barriers. Fourth, distribution strategies need to be nuanced: integrating hospital pharmacies for injectable administration, leveraging online pharmacies for easier access to oral products, and partnering with chain and independent retail pharmacies for counseling and ongoing dispensing will broaden reach. Finally, public-private collaboration-spanning community organizations, health departments, and companies-can accelerate culturally competent outreach and retention, ensuring that scientific advances translate into equitable prevention outcomes.

Transparent, evidence-based research methodology that integrates stakeholder insights, regulatory review, and operational analysis to inform strategic decisions

The research underpinning these insights combined a multimodal approach centered on primary stakeholder engagement, clinical evidence synthesis, and operational analysis. We conducted structured interviews with clinicians, pharmacists, payer representatives, procurement officers, and patient advocates to capture frontline perspectives on prescribing behavior, adherence barriers, and channel dynamics. These qualitative inputs were triangulated with a systematic review of regulatory approvals, guideline revisions, and published clinical trial outcomes to ensure technical accuracy and relevance to current practice.

Operational dimensions relied on supply chain mapping, procurement process examination, and scenario analysis of policy developments such as tariff adjustments. Comparative case studies across different health systems informed regional differentiation and distribution channel assessment. Throughout, methodological rigor emphasized transparent data sourcing, cross-validation of interview findings with publicly available regulatory documents, and iterative expert review to refine interpretations. This blended methodology supports conclusions that are both evidence-based and pragmatic for decision makers seeking to translate insights into operational strategies.

Concluding synthesis that integrates clinical advances, delivery imperatives, and policy considerations to guide pragmatic PrEP decision making

In conclusion, the PrEP landscape is in a state of strategic transition driven by therapeutic innovation, evolving care models, and shifting policy levers. Long-acting injectables introduce promising adherence and retention advantages but require reconfigured delivery pathways and payer engagement to realize their full potential. Daily oral formulations remain indispensable for broad, decentralized access, especially where pharmacy and online channels facilitate initiation and persistence. The interplay of product type, administration route, end-user needs, distribution channels, and mechanism of action creates a complex but navigable decision matrix for manufacturers, payers, and providers.

External factors, including trade policy changes and regional system characteristics, add urgency to supply chain diversification and stakeholder collaboration. Organizations that align clinical differentiation with pragmatic distribution strategies, robust payer engagement, and culturally competent outreach will be best positioned to expand prevention coverage. Ultimately, converting scientific progress into population impact requires coordinated action across the commercial, clinical, and public health spheres to ensure that effective PrEP options reach those who can benefit most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drugs for PrEP Market, by Product Type

  • 8.1. Branded
    • 8.1.1. Apretude
    • 8.1.2. Descovy
    • 8.1.3. Truvada
  • 8.2. Generic

9. Drugs for PrEP Market, by Administration Route

  • 9.1. Injectable
  • 9.2. Oral

10. Drugs for PrEP Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy
    • 10.3.1. Chain Pharmacy
    • 10.3.2. Independent Pharmacy

11. Drugs for PrEP Market, by Mechanism Of Action

  • 11.1. Integrase Strand Transfer Inhibitors
  • 11.2. Nucleotide Reverse Transcriptase Inhibitors

12. Drugs for PrEP Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Drugs for PrEP Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Drugs for PrEP Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Drugs for PrEP Market

16. China Drugs for PrEP Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Astellas Pharma Inc.
  • 17.7. Aurobindo Pharma Limited
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Bristol Myers Squibb Company
  • 17.10. Cipla Limited
  • 17.11. Emcure Pharmaceuticals Limited
  • 17.12. Gilead Sciences, Inc.
  • 17.13. GlaxoSmithKline plc
  • 17.14. Hetero Labs Limited
  • 17.15. Janssen Pharmaceuticals, Inc.
  • 17.16. Lupin Limited
  • 17.17. Macleods Pharmaceuticals Ltd.
  • 17.18. Merck KGaA
  • 17.19. Mylan N.V.
  • 17.20. Novartis AG
  • 17.21. Pfizer Inc.
  • 17.22. Sanofi SA
  • 17.23. Sun Pharmaceutical Industries Ltd.
  • 17.24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUGS FOR PREP MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUGS FOR PREP MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUGS FOR PREP MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUGS FOR PREP MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUGS FOR PREP MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUGS FOR PREP MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUGS FOR PREP MARKET SIZE, BY APRETUDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUGS FOR PREP MARKET SIZE, BY APRETUDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUGS FOR PREP MARKET SIZE, BY APRETUDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DESCOVY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DESCOVY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DESCOVY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUGS FOR PREP MARKET SIZE, BY TRUVADA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUGS FOR PREP MARKET SIZE, BY TRUVADA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUGS FOR PREP MARKET SIZE, BY TRUVADA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUGS FOR PREP MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUGS FOR PREP MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUGS FOR PREP MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUGS FOR PREP MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUGS FOR PREP MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUGS FOR PREP MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUGS FOR PREP MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUGS FOR PREP MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUGS FOR PREP MARKET SIZE, BY NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUGS FOR PREP MARKET SIZE, BY NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUGS FOR PREP MARKET SIZE, BY NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUGS FOR PREP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS DRUGS FOR PREP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUGS FOR PREP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 118. GCC DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. GCC DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 139. G7 DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. G7 DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 142. G7 DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 143. NATO DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 146. NATO DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. NATO DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. NATO DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 149. NATO DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DRUGS FOR PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA DRUGS FOR PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA DRUGS FOR PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA DRUGS FOR PREP MARKET SIZE, BY BRANDED, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA DRUGS FOR PREP MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA DRUGS FOR PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA DRUGS FOR PREP MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA DRUGS FOR PREP MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)